Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice Regarding the Large-Scale Exercise of the 17th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment

Of the 17th Series Stock Acquisition Rights allotted to EVO FUND, 20,800 rights were exercised between 1 and 14 April 2026, resulting in the delivery of 2,080,000 new shares. The number of unexercised stock acquisition rights decreased from 37,800 to 17,000.

Worth reading
60In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2080000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Bulk exercise of stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment

発行・処分する株式数

2,080,000 new shares (transferred treasury shares: 0)

Intended allottee
EVO FUND (allottee of the previously issued stock acquisition rights)
Terms of the stock acquisition rights
Exercise price
¥57.0, ¥59.0, ¥58.0, ¥54.0, ¥55.0 and ¥53.0 (exercise price on each exercise date). Details of the adjustment clause and the floor price were not disclosed.
Number of Stock Acquisition Rights
Total issued: 192,000 rights. 20,800 rights were exercised from the beginning of the month, leaving 17,000 unexercised rights as of the current date.
Most recent equity financing
Issued on 25 August 2025: the 17th Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) and the 1st Series Unsecured Bonds (private placement), issued through a third-party allotment. The amount was not disclosed.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalBulk exercise of stock acquisition rights with an exercise price adjustment clause issued through a third-party allotment
Number of shares to be issued or disposed of2,080,000 new shares (transferred treasury shares: 0)
Intended allotteeEVO FUND (allottee of the previously issued stock acquisition rights)
Total number of issued shares92,354,098 shares (as of the end of the month preceding the subject month) → Not disclosed
Exercise price¥57.0, ¥59.0, ¥58.0, ¥54.0, ¥55.0 and ¥53.0 (exercise price on each exercise date). Details of the adjustment clause and the floor price were not disclosed.
Number of Stock Acquisition RightsTotal issued: 192,000 rights. 20,800 rights were exercised from the beginning of the month, leaving 17,000 unexercised rights as of the current date.
Most recent equity financingIssued on 25 August 2025: the 17th Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) and the 1st Series Unsecured Bonds (private placement), issued through a third-party allotment. The amount was not disclosed.
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This reports the fact of the substantial exercise; the company has not stated the reason for the exercise.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Large-Scale Exercise of the 17th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued Through a Third-Party Allotment | Modalis Therapeutics Corporation (4883) timely disclosure | Komori